Business Context and Reporting Period
This Form 8-K Current Report from Matinas Biopharma Holdings, Inc. (MTNB) covers events occurring on November 1, 2019, specifically the results of the Company's Annual Meeting of Stockholders. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on three primary proposals at the Annual Meeting:
- Director Elections: Stockholders elected seven individuals to the Board of Directors for a term ending in 2020. All nominees received significant "For" votes, ranging from approximately 65.3 million to 66.0 million, with "Withheld" votes ranging from approximately 4.0 million to 4.7 million. Notably, there were 50,786,138 broker non-votes for each director election.
- Independent Auditor Ratification: Stockholders approved the ratification of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019. The vote was 120,123,889 "For" versus 6,324,918 "Against" and 707,04 "Abstain".
- Capital Structure Amendment: Stockholders approved an amendment to the Certificate of Incorporation to increase the maximum number of authorized common shares from 250,000,000 to 500,000,000. The vote was 112,169,630 "For" versus 8,104,943 "Against" and 554,938 "Abstain".
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies beyond the standard corporate actions reported. The text notes that the description of the Certificate of Incorporation amendment is qualified by reference to the full text attached as Exhibit 3.1.
Investor Verification Checklist
- Verify the final composition of the Board of Directors following the election of the seven new directors.
- Confirm the effective date and legal filing of the Certificate of Amendment increasing authorized shares to 500,000,000 (Exhibit 3.1).
- Review the definitive proxy statement filed on September 24, 2019, for detailed background on the proposals.
- Note the high volume of broker non-votes (approx. 50.8 million) in the director elections, which may indicate significant institutional holdings where brokers lacked discretionary voting power.